

October 20, 2024

DCS-CRD **BSE Limited** First Floor, New Trade Wing

Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001

Fax No.2272 3121/2037/2039

Stock Code: 543213

Listing Compliance

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor

Plot No. C/1, 'G' Block, Bandra- Kurla Complex

Bandra East Mumbai 400051 Fax No.2659 8237/8238

Stock Code: ROSSARI

Dear Sir/Madam,

Subject.: Q2 FY25 Press Release

Please find enclosed a copy of the Press Release for the Quarter and half year ended September 30, 2024.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

For Rossari Biotech Limited





Parul Gupta

Head - Company Secretary & Legal

Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office: 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. T: +91-22-6123 3800 F: +91-22-2579 6982 Factory: Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000 : Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621





www.rossari.com









Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens, Kanjurmarg West, Mumbai, Maharashtra 400078

Rossari Biotech announces Q2 FY25 results

Q2 FY25

- > Revenues at Rs. 498.4 Cr, up 3.1% YoY
- > EBITDA at Rs. 65.9 Cr, up 3.6% YoY
- > PAT at Rs. 35.3 Cr, up 7.3% YoY

Mumbai, November 20, 2024: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended September 30, 2024.

Consolidated: Q2 FY25 performance overview compared with Q2 FY24

- Revenue from operations grew 3.1% to Rs. 498.4 crore as compared to Rs. 483.5 crore
- EBITDA improved by 3.6% to Rs. 65.9 crore from Rs. 63.6 crore
 - EBITDA margin at 13.2% as against 13.1%
- PAT increased by 7.3% to Rs. 35.3 crore from Rs. 32.9 crore
- EPS (Diluted) stood at Rs. 6.4* as against Rs. 6.0*

Consolidated: H1 FY25 performance overview compared with H1 FY24

- Revenue from operations stood at Rs. 988.0 crore as against Rs. 894.1 crore, up 10.5%
- EBITDA increased by 7.8% to Rs. 130.8 crore as against Rs. 121.3 crore
 - EBITDA margin at 13.2% as against 13.6%
- PAT higher by 12.9% to Rs. 70.2 crore as against Rs. 62.2 crore
- EPS (Diluted) stood at Rs. 12.7* as against Rs.11.3*

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) * EPS not annualized



Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

"We have reported a steady performance this quarter, reflecting the resilience of our business amidst a dynamic market environment. Our HPPC division continues to demonstrate consistent growth, while the Textile business is still navigating headwinds, with a recovery expected in the next calendar year. AHN Business remained stable during the quarter.

On the export front, we are proud to have expanded our global operations, with several geographies emerging as key drivers of future growth. We registered a strong performance in our export markets by targeting new customers in both new and existing geographies and increasing our wallet share with our partners. In H1 FY25, exports grew by 32%, providing support to overall performance amidst softer domestic growth. While the domestic market is also poised for expansion, we expect exports to outpace domestic growth, further strengthening our position in international markets.

We continue to pioneer intelligent and sustainable solutions across industries, enhancing everyday life through our eco-friendly and technology-driven offerings. Our focus on innovation and customer-centric solutions enables us to stay ahead of industry trends, delivering value through products that are both high in quality and sustainability.

With a diversified product portfolio, agile manufacturing capabilities, and a strong balance sheet, we believe we are well-positioned to capitalize on emerging opportunities and drive healthy growth for the foreseeable future. As a growth-focused Company, we remain committed to innovation, continuously developing tailored solutions that meet the evolving needs of our customers. We are working towards expanding our global footprint through our own manufacturing set up and sales & distribution network overseas. This approach strengthens our confidence in delivering sustainable operational and financial performance while creating long-term value for all our stakeholders."



Key Developments

Expanding Global Presence Driving Growth

- Rossari Global DMCC, a wholly owned subsidiary of Rossari Biotech Limited (Rossari), has incorporated a step-down wholly owned subsidiary, Rossari Biotech Trading FZE, in the Jebel Ali Free Zone (JAFZA), UAE. This new entity will focus on trading activities, including managing the distribution and sales of chemicals and consumer products for export market
- Rossari Global DMCC, wholly owned subsidiary of Rossari has agreed to acquire 100% of the total equity share capital of Unistar Thai Co. Limited ("Unistar"), from all the existing shareholders of Unistar, subject to completion of customary terms and conditions precedent. Unistar is a newly incorporated company and yet to commence its operation. This entity will focus on manufacturing and sale of specialty chemicals related to the chemistries in which Rossari operates

Land Purchase for Future Expansion

 Rossari has purchased a plot of land measuring ~39,101 square meters adjoining its existing Dahej facility, for a total consideration of ~ Rs. 15 crore and such other charges as per the terms of GIDC. This land will be utilised for future expansion and development of existing facility

Appointment of Mr. Gurudas Aras as Non-Executive Independent Director

- The Company appointed Mr. Gurudas Aras as an Additional Director designated as Non-Executive Independent Director with effect from October 19, 2024.
- Mr. Aras is the former Director of the Textile Engineering Group at A.T.E. Group and also on the advisory board and board of Studies of VJTI, Mumbai. He has more than 40 years of experience in the textile industry.
- Currently, he also serves as a strategic advisor to APS GmbH, a German company in the field of robotics and automation and is a Business Advisor to Rabatex Industries and Yamuna Machine Works, both from the textile engineering field. Mr. Aras holds a Bachelor's degree in Textile Engineering from Bombay University with a Gold Medal and first rank with distinction. He also earned his Master's degree in Textile Engineering in 1982, followed by a Post Graduate Diploma in Marketing Management from Bombay University in 1984. He is also a certified Crisil ESG Risk Analyst.

< Ends >

Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)



About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Ketan Sablok

Rossari Biotech Limited Tel: +91 22 6123 3800

Email: ketan.sablok@rossari.com

Anoop Poojari / Mitesh Jain

CDR India

Tel: +91 98330 90434 / 96194 44691

Email:anoop@cdr-india.com / mitesh@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.